Physician profile
John C Boston
NPI 1982666137
$5,661.13
in general payments reported to CMS, 2019-2025
42 companies · $67.69 in 2025
The $67.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $1,104 · 2021: $1,747 · 2022: $979 · 2023: $441 · 2025: $67.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $829.55 | 2019-2025 | Breztri, Farxiga |
| Abbvie INC. | $727.13 | 2019-2023 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $602.77 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $403.87 | 2019-2022 | |
| Lilly USA, LLC | $346.46 | 2019-2023 | Trulicity, Mounjaro |
| Pfizer INC. | $237.69 | 2019-2023 | |
| Amgen INC. | $230.52 | 2019-2023 | Enbrel |
| Allergan, INC. | $186.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $186.97 | 2019-2021 | |
| Astellas Pharma US INC | $180.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $144.88 | 2019-2022 | |
| Medtronic, INC. | $144.20 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $136.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $117.71 | 2019-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $114.48 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Boston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.